Pacira BioSciences
PCRX
226 hedge funds and large institutions have $1.58B invested in Pacira BioSciences in 2020 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 82 increasing their positions, 72 reducing their positions, and 38 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 72
2.96% more ownership
Funds ownership: 108.97% → 111.93% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 38
2% less funds holding
Funds holding: 231 → 226 (-5)
23% less call options, than puts
Call options by funds: $8.82M | Put options by funds: $11.5M
23% less capital invested
Capital invested by funds: $2.06B → $1.58B (-$483M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$67.6M |
| 2 |
Renaissance Technologies
New York
|
+$27.9M |
| 3 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$13.9M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$10.8M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$9.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$15.2M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$11.2M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$10.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$8.28M |
PCRX Hedge Fund Activity: Q1 2020 in Review
226 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2020, worth a combined $1.58B — down 23% from $2.06B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of PCRX and 35 opened new positions — a net loss of 3 holders — while 72 trimmed existing stakes and 82 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $67.6M. The largest seller was Macquarie Group, cutting an estimated $15.2M.
- 226 institutional investors held Pacira BioSciences (PCRX) as of Q1 2020, down from 231 in Q4 2019.
- Funds reported $1.58B of Pacira BioSciences stock for Q1 2020, down 23% quarter-over-quarter.
- 35 funds opened new Pacira BioSciences positions in Q1 2020 and 38 closed out, a net change of -3 holders.
- The largest Pacira BioSciences buyer in Q1 2020 was Deerfield Management, an estimated $67.6M added.
- The largest Pacira BioSciences seller in Q1 2020 was Macquarie Group, an estimated $15.2M sold.
Based on aggregated 13F filings for Q1 2020.